Repurposing Clinically Safe Drugs to Direct DNA Repair in CRISPR Genome Editing

Study Background and Research Question

Genome editing technologies such as CRISPR-Cas9 have revolutionized biomedical research and therapeutic development by enabling targeted induction of DNA double-strand breaks (DSBs) at specified genomic loci. However, the cellular repair of these breaks is governed by multiple pathways—primarily non-homologous end joining (NHEJ), microhomology-mediated end joining (MMEJ), and homology-directed repair (HDR)—each influencing the efficiency and precision of genome modifications. NHEJ and MMEJ often introduce indels or deletions, while HDR allows for precise sequence changes when an appropriate template is supplied. The ability to control which pathway predominates during genome editing is critical for disease modeling, gene therapy, and synthetic lethality strategies in oncology. The central research question addressed by the reference study is whether existing clinically approved drugs can be repurposed to selectively modulate DSB repair pathway choice and thereby influence genome editing outcomes.

Key Innovation from the Reference Study

The principal innovation of this work is a high-throughput, systematic screening of the majority of FDA-approved drugs to identify those capable of shifting the balance among DSB repair pathways during CRISPR-mediated genome editing in human induced pluripotent stem cells (iPSCs). By interrogating over 7,000 compounds, the authors have mapped a pharmacological landscape that reveals new levers for guiding cellular repair responses, including both inhibitors and enhancers of NHEJ, MMEJ, and HDR. Notably, the study also uncovers drugs that induce synthetic lethality when NHEJ or HDR is pharmacologically blocked, providing candidate molecules for precision cancer therapy. The resource is uniquely valuable for its emphasis on clinically safe drugs, facilitating rapid translational potential.

Methods and Experimental Design Insights

The authors employed a robust, multi-step workflow for drug repurposing:

• Human iPSCs (409B2 line) were engineered with a doxycycline-inducible Cas9 system (iCRISPR) to generate targeted DSBs at the FRMD7 locus.
• Cells were exposed to individual drugs from a library of over 7,000 FDA-approved compounds during genome editing.
• After drug treatment and editing, cells were recovered in normal media, and survival was quantified using a resazurin fluorescence assay.
• Genomic DNA was extracted from surviving cells, and high-throughput Illumina sequencing was used to characterize mutational outcomes, assigning repair events to NHEJ, MMEJ, or HDR.
• The resulting data enabled quantitative assessment of how each compound influenced the distribution of repair outcomes and cell viability.

This approach allowed for the parallel evaluation of drugs' effects on both the efficiency and fidelity of genome editing, as well as their potential to induce synthetic lethality under specific pathway inhibition conditions.

Core Findings and Why They Matter

Key findings from the screen include:

• Identification of multiple drugs that significantly shift the balance between NHEJ, MMEJ, and HDR during CRISPR editing, enabling more precise control over desired editing outcomes (reference).
• Discovery that inhibition of estrogen receptor 2 (ESR2) synergizes with NHEJ inhibitors to increase HDR rates up to 4.6-fold, presenting a strategy to enhance precision gene correction.
• Mapping of drugs capable of inducing synthetic lethality when core repair pathways are pharmacologically blocked—offering new candidates for targeted cancer therapies based on repair vulnerabilities.
• Revealing new roles for ESR2 and aldehyde oxidase 1 (AOX1) in modulation of the DNA damage response, with downstream effects on key repair proteins such as ATM and 53BP1.

These findings are highly significant for both basic research and clinical translation. For example, in gene therapy applications where precise sequence correction is essential, manipulating drug conditions to favor HDR over NHEJ/MMEJ can improve therapeutic efficacy and safety. Likewise, synthetic lethality strategies identified here could inform the development of combination therapies that selectively target cancer cells with repair deficiencies.

Comparison with Existing Internal Articles

Several recent reviews and research articles have discussed the role of pharmacological agents in modulating DNA repair and genome editing outcomes. For instance, Drug Repurposing Modulates DNA Repair Pathways in CRISPR Editing provides a focused overview of how small molecules can be leveraged to alter DSB repair pathway choice, echoing the systematic screening approach of the current reference study. Similarly, Repurposing Clinically Safe Drugs to Modulate DNA Repair Pathways emphasizes the translational potential of using FDA-approved compounds for precision genome engineering in disease models. These internal discussions align with the present study's demonstration that pathway-modulating drugs can be rationally selected to control editing outcomes, as well as to exploit synthetic lethality in cancer research. However, the reference study distinguishes itself by its breadth and quantitative mapping of repair outcomes across thousands of drugs, providing an empirical foundation that complements and extends prior conceptual frameworks.

Additionally, research on calcium signaling and ryanodine receptor antagonists, such as Dantrolene sodium salt, has underscored the interplay between calcium homeostasis and DNA damage responses, suggesting further opportunities for cross-pathway modulation in genome editing and synthetic lethality workflows.

Limitations and Transferability

While the large-scale screen offers valuable insights, several limitations should be considered. First, the assays were performed in a single human iPSC line and at a single genomic locus, which may limit the generalizability of pathway modulation effects to other cell types or editing targets. Second, although the study focused on clinically safe drugs, the concentrations and exposure durations used in vitro may not always translate to relevant in vivo conditions. Third, the functional consequences of shifting repair pathway balance—for example, increased off-target effects or large deletions—require further investigation, particularly for therapeutic applications. Finally, synthetic lethality effects observed here must be validated in disease-relevant models to confirm selectivity and minimize toxicity to normal tissues.

Protocol Parameters

• CRISPR editing window: Induce DSBs via Cas9 expression for 24–48 hours in human iPSCs under doxycycline control.
• Drug exposure: Apply candidate FDA-approved compounds at literature-supported concentrations during genome editing; consult primary screening data for optimal dosing.
• Repair outcome assessment: Extract DNA 2–3 days post-editing for high-throughput sequencing to quantify indels, deletions, and HDR events.
• Cell viability assay: Perform resazurin-based fluorescence readout to quantify survival after editing and drug treatment.
• Pathway synergy evaluation: For synthetic lethality studies, combine inhibitors targeting distinct repair mechanisms following single-agent validation.

Research Support Resources

To facilitate similar investigations into DNA repair modulation and synthetic lethality, researchers may require reliable modulators of intracellular calcium and ryanodine receptor signaling. Dantrolene, sodium salt (SKU B6329) from APExBIO is a well-characterized ryanodine receptor antagonist with documented efficacy in calcium signaling modulation and gene-editing workflows. Its high purity and established use in disease and neurodegenerative models support its application as a research-grade compound for controlling calcium-dependent repair processes. Detailed specifications, solubility profiles, and storage guidelines are available in the product dossier and can assist in protocol optimization for genome editing and synthetic lethality experiments.